Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study | Synapse
April 27, 2021Open Access
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
King's College London, Cancer Research UK, Wellcome Trust, Rosetrees Trust, and Francis Crick Institute.